ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene (Nasdaq: EVGN) has announced a definitive agreement for ICL to acquire the majority of activities of its subsidiary, Lavie Bio , along with Evogene's MicroBoost AI for AG platform. The transaction is expected to close in Q2 2025.
The acquisition includes Lavie Bio's core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. Lavie Bio's existing partner agreements will remain with current shareholders. This deal follows ICL Planet's strategic investment and over two years of collaboration between ICL and Lavie Bio in developing bio-stimulant solutions for row crops.
Lavie Bio specializes in microbiome-based ag-biological products aimed at improving agricultural productivity and sustainability. The integration aims to accelerate the development of innovative agricultural solutions globally.
Evogene (Nasdaq: EVGN) ha annunciato un accordo definitivo per l'acquisizione da parte di ICL della maggior parte delle attivit脿 della sua controllata, Lavie Bio, insieme alla piattaforma MicroBoost AI for AG di Evogene. La transazione 猫 prevista per il secondo trimestre del 2025.
L'acquisizione comprende il team principale di Lavie Bio, la piattaforma tecnologica BDD, la banca microbica, i dati, i programmi di sviluppo e i prodotti commerciali. Gli accordi di partnership esistenti di Lavie Bio rimarranno con gli azionisti attuali. Questo accordo segue l'investimento strategico di ICL Planet e oltre due anni di collaborazione tra ICL e Lavie Bio nello sviluppo di soluzioni bio-stimolanti per colture agricole.
Lavie Bio 猫 specializzata in prodotti ag-biol貌gici basati sul microbioma, volti a migliorare la produttivit脿 agricola e la sostenibilit脿. L'integrazione mira ad accelerare lo sviluppo di soluzioni agricole innovative a livello globale.
Evogene (Nasdaq: EVGN) ha anunciado un acuerdo definitivo para que ICL adquiera la mayor铆a de las actividades de su subsidiaria, Lavie Bio, junto con la plataforma MicroBoost AI for AG de Evogene. Se espera que la transacci贸n se cierre en el segundo trimestre de 2025.
La adquisici贸n incluye el equipo principal de Lavie Bio, la plataforma tecnol贸gica BDD, el banco microbiano, los activos de datos, los programas de desarrollo y los productos comerciales. Los acuerdos de asociaci贸n existentes de Lavie Bio permanecer谩n con los accionistas actuales. Este acuerdo sigue a la inversi贸n estrat茅gica de ICL Planet y a m谩s de dos a帽os de colaboraci贸n entre ICL y Lavie Bio en el desarrollo de soluciones bioestimulantes para cultivos extensivos.
Lavie Bio se especializa en productos agrobiol贸gicos basados en microbiomas, destinados a mejorar la productividad agr铆cola y la sostenibilidad. La integraci贸n busca acelerar el desarrollo de soluciones agr铆colas innovadoras a nivel mundial.
Evogene (雮橃姢雼�: EVGN)電� ICL鞚� 鞛愴殞靷� Lavie Bio鞚� 欤检殧 靷梾瓿� Evogene鞚� MicroBoost AI for AG 頂岆灚韽检潉 鞚胳垬頃橂姅 斓滌 瓿勳暯鞚� 觳搓舶頄堧嫟瓿� 氚滍憸頄堨姷雼堧嫟. 瓯半灅電� 2025雲� 2攵勱赴鞐� 毵堧毽悹 鞓堨爼鞛呺媹雼�.
鞚措矆 鞚胳垬鞐愲姅 Lavie Bio鞚� 頃奠嫭 韺�, BDD 旮办垹 頂岆灚韽�, 氙胳儩氍� 鞚�頄�, 雿办澊韯� 鞛愳偘, 臧滊皽 頂勲攴鸽灗 氚� 靸侅梾 鞝滍拡鞚� 韽暔霅╇媹雼�. Lavie Bio鞚� 旮办〈 韺岉姼雱堨嫮 瓿勳暯鞚� 順勳灛 欤检＜鞕� 鞙犾霅╇媹雼�. 鞚措矆 瓯半灅電� ICL Planet鞚� 鞝勲灥鞝� 韴瀽鞕� ICL瓿� Lavie Bio 臧� 2雲� 鞚挫儊鞚� 順戨牓 雭濎棎 鞚措（鞏挫鞙茧┌, 欤茧 氚瀾氍检毄 靸濎泊 齑夓鞝� 靻旊（靺� 臧滊皽鞐� 歆戩頄堨姷雼堧嫟.
Lavie Bio電� 雴嶌梾 靸濎偘靹标臣 歆�靻� 臧�電レ劚 頄レ儊鞚� 氇╉憸搿� 頃橂姅 氙胳儩氍缄蛋歆� 旮半皹鞚� 雴嶌梾 靸濍頃欖爜 鞝滍拡鞚� 鞝勲鞙茧 頃╇媹雼�. 鞚措矆 韱淀暕鞚� 鞝� 靹戈硠鞝侅溂搿� 順侅嫚鞝侅澑 雴嶌梾 靻旊（靺� 臧滊皽鞚� 臧�靻嶍檾頃橂姅 瓴冹潉 氇╉憸搿� 頃╇媹雼�.
Evogene (Nasdaq : EVGN) a annonc茅 un accord d茅finitif pour qu'ICL acqui猫re la majorit茅 des activit茅s de sa filiale, Lavie Bio, ainsi que la plateforme MicroBoost AI for AG d'Evogene. La transaction devrait 锚tre finalis茅e au deuxi猫me trimestre 2025.
L'acquisition comprend l'茅quipe principale de Lavie Bio, la plateforme technologique BDD, la banque microbienne, les donn茅es, les programmes de d茅veloppement et les produits commerciaux. Les accords de partenariat existants de Lavie Bio resteront avec les actionnaires actuels. Cet accord fait suite 脿 l'investissement strat茅gique d'ICL Planet et 脿 plus de deux ans de collaboration entre ICL et Lavie Bio pour d茅velopper des solutions bio-stimulantes pour les cultures de plein champ.
Lavie Bio est sp茅cialis茅e dans les produits agro-biologiques bas茅s sur le microbiome, visant 脿 am茅liorer la productivit茅 agricole et la durabilit茅. L'int茅gration vise 脿 acc茅l茅rer le d茅veloppement de solutions agricoles innovantes 脿 l'茅chelle mondiale.
Evogene (Nasdaq: EVGN) hat eine endg眉ltige Vereinbarung bekannt gegeben, wonach ICL den Gro脽teil der Aktivit盲ten seiner Tochtergesellschaft Lavie Bio sowie die MicroBoost AI for AG-Plattform von Evogene 眉bernehmen wird. Der Abschluss der Transaktion wird f眉r das zweite Quartal 2025 erwartet.
Die 脺bernahme umfasst das Kernteam von Lavie Bio, die BDD-Technologieplattform, die Mikrobenbank, Datenbest盲nde, Entwicklungsprogramme und kommerzielle Produkte. Die bestehenden Partnervereinbarungen von Lavie Bio verbleiben bei den aktuellen Anteilseignern. Dieser Deal folgt auf die strategische Investition von ICL Planet und 眉ber zwei Jahre Zusammenarbeit zwischen ICL und Lavie Bio bei der Entwicklung von Bio-Stimulanzien f眉r Feldfr眉chte.
Lavie Bio ist auf mikrobiombasierte ag-biologische Produkte spezialisiert, die darauf abzielen, die landwirtschaftliche Produktivit盲t und Nachhaltigkeit zu verbessern. Die Integration soll die Entwicklung innovativer landwirtschaftlicher L枚sungen weltweit beschleunigen.
- Strategic acquisition strengthens market position in ag-biologicals sector
- Retention of revenue potential from existing partnership agreements
- Built on established successful collaboration with ICL Planet
- Transaction unlocks immediate value for Evogene shareholders
- Loss of majority control over Lavie Bio's operations
- Divestment of key technological assets including MicroBoost AI platform
Insights
ICL's acquisition of Lavie Bio's operations represents a strategic divestiture for Evogene, unlocking shareholder value through monetization of its subsidiary's assets.
This transaction demonstrates a structured approach to asset monetization by Evogene. The definitive agreement transfers substantial portions of Lavie Bio's operations to ICL, including the core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. Additionally, Evogene's MicroBoost AI for AG platform will be acquired.
The deal structure includes an important retention element: Lavie Bio's existing partner agreements will remain with the original shareholders, potentially generating future revenue streams. This suggests a thoughtful value preservation mechanism rather than a complete exit.
What's particularly notable is that this transaction follows both a strategic investment by ICL Planet and over two years of collaboration between the companies. This progression from partnership to acquisition indicates a carefully cultivated business relationship that evolved organically.
With an expected closing in Q2 2025 subject to customary conditions, this deal represents the culmination of Evogene's explicitly stated strategy to "unlock the value of its assets for the benefit of its shareholders." While financial terms aren't disclosed, the transaction appears to be a significant milestone in Evogene's corporate development.
The acquisition of Lavie Bio's operations by ICL represents a significant consolidation in the ag-biologicals sector. Lavie Bio has established itself as a recognized leader in microbiome-based agricultural biologicals with a robust product pipeline.
What makes this transaction technically significant is the comprehensive nature of the transferred assets: the BDD technology platform, microbial bank, and data assets represent years of specialized R&D work in agricultural biologicals. These biologicals improve agriculture productivity and sustainability 鈥� critical objectives as global farming faces increasing environmental challenges.
The MicroBoost AI for AG platform acquisition is especially noteworthy as it represents Evogene's computational biology capabilities specifically tailored for agricultural applications. This AI-driven platform accelerates discovery and development of microbial-based products that can enhance crop resilience to various stresses.
The previous two-year collaboration between these companies focused specifically on "developing innovative bio-stimulant solutions for row crops facing various abiotic stresses" 鈥� addressing a growing market need as climate change increases environmental pressures on agriculture. This prior relationship suggests ICL recognized sufficient value in Lavie Bio's technological approach to move from collaboration to acquisition, potentially accelerating the commercialization of these agricultural biological solutions.
Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products
REHOVOT,
听
听
The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.
Lavie Bio is a recognized leader in the ag-biologicals industry听with a robust pipeline of microbiome-based ag-biological products. Key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, the company's microbial bank and data assets, the majority of the company's development programs, and its commercial products. Additionally, ICL will acquire Evogene's MicroBoost AI for AG platform. Lavie Bio's existing agreements with its current partners will not be transferred to ICL and may generate future revenue for Lavie Bio's shareholders.
This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for row crops facing various abiotic stresses.
"Today marks a significant milestone in Lavie Bio's journey," said Amit Noam, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world."听
"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said Ofer Haviv, CEO of Evogene. "We are confident that the integration of Lavie Bio's activities into ICL will significantly advance the global ag-biologicals field and drive impactful innovation in agriculture."
About Lavie Bio Ltd.
Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's proprietary MicroBoost AI tech-engine, harnessing the power of big data, artificial intelligence, and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products.
For more information, please visit .
About Evogene Ltd.
Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines 鈥� MicroBoost AI, ChemPass AI and GeneRator AI 鈥� leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit .
Forward Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss the fulfilment of the closing conditions to the transaction, ICL and Lavie Bio's ability to accelerate the development of groundbreaking ag-biological products,听and the statement that the integration of Lavie Bio's activities into ICL will significantly advance the global ag-biologicals field and drive impactful innovation in agriculture. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Evogene Investors听Relations Contact:
Email: [email protected]
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/945133/lavie_bio.jpg 听
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
听
听
View original content:
SOURCE Lavie Bio
FAQ
What assets is ICL acquiring from Evogene's Lavie Bio subsidiary?
When will the ICL-Lavie Bio acquisition (EVGN) close?
What happens to Lavie Bio's existing partnership agreements after the ICL acquisition?
How long have ICL and Lavie Bio (EVGN) been collaborating before the acquisition?
